Drilling Down Into Exelixis, Inc. (EXEL)

Exelixis, Inc. (EXEL) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $21.56, up from yesterday’s close by 5.63%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.

Fundamental Analysis

Exelixis, Inc. (EXEL) currently trades with a market capitalization of $7.10 Billion. That value represents a market adjusting for revenues that have been growing by 162.52 % on a quarterly year/year basis as of the company’s last quarterly report.

You can get a sense of how sustainable that is by a levered free cash flow of $145.28 Million over the past twelve months. Generally speaking, earnings are expected to fall in coming quarters. Analysts are forecasting earnings of $0.16 on a per share basis this quarter. Perhaps, that suggests something about why 1.66% of the outstanding share supply is held by institutional investors.

Technical Analysis

Sometimes, we can understand most about a stock by simply looking at how it has been trading. Looking at the stock’s movement on the chart, Exelixis, Inc. recorded a 52-week high of $32.50. It is now trading 10.94% off that level. The stock is trading $21.93 its 50-day moving average by 0.37%. The stock carved out a 52-week low down at $18.03.

In recent action, Exelixis, Inc. (EXEL) has made a move of +2.23% over the past month, which has come on Strong relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 15.08, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 3.27% with $286.23 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of EXEL.

Previous articleChevron Corporation (CVX): From Top to Bottom
Next articleThe Case for and Against Halcon Resources Corporation (HK)